JAZZ News and Press, Jazz Pharmaceuticals plc From 12/09/19

Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Jazz Pharmaceuticals' (NASDAQ: JAZZ ) solriamfetol to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstr...

DUBLIN , Nov. 15, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorisation of solriamfetol to impro...

DUBLIN , Nov. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor conferences. Jefferies 2019 London Healthcare Conference in London, UK on Thursday, November 21, 2019 ...

15 abstracts spanning Jazz's hematology/oncology therapeutic area focusing on acute leukemias and complications of stem cell transplantation New sub-analysis of Vyxeos Phase 3 trial data accepted as an oral presentation DUBLIN , Nov. 7, 2019 /PRNewswire/ -- Jazz Pharmaceutica...

Image source: The Motley Fool. Jazz Pharmaceuticals   (NASDAQ: JAZZ) Q3 2019 Earnings Call Nov 05, 2019 , 4:30 p.m. ET Operator Continue reading

Jazz Pharmaceuticals plc (JAZZ) Q3 2019 Results Earnings Conference Call November 5, 2019, 04:30 PM ET Company Participants Katherine Littrell - Vice President, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Daniel Swisher, Jr. - President and Chief Operat...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q3 results : More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Read more ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2019 Q3 earnings Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q3 Non-GAAP EPS of $4.10 beats by $0.51 ; GAAP EPS of $1.78 misses by $0.32 . Revenue of $537.7M (+14.6% Y/Y) beats by $13.78M . Shares +5.6% . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Stocks on th...